401 related articles for article (PubMed ID: 24673487)
1. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
2. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
[TBL] [Abstract][Full Text] [Related]
4. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
[TBL] [Abstract][Full Text] [Related]
5. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Alvarez R; Larrosa D; Ramón C; Pascual J
Cephalalgia; 2015 Apr; 35(4):310-6. PubMed ID: 24847167
[TBL] [Abstract][Full Text] [Related]
6. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients.
Riesco N; Cernuda-Morollón E; Martínez-Camblor P; Pérez-Alvarez AI; Verano L; García-Cabo C; Serrano-Pertierra E; Pascual J
Cephalalgia; 2017 Aug; 37(9):823-827. PubMed ID: 27250233
[TBL] [Abstract][Full Text] [Related]
9. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Bellamy JL; Cady RK; Durham PL
Headache; 2006 Jan; 46(1):24-33. PubMed ID: 16412148
[TBL] [Abstract][Full Text] [Related]
10. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders.
Sarchielli P; Pini LA; Zanchin G; Alberti A; Maggioni F; Rossi C; Floridi A; Calabresi P
Cephalalgia; 2006 Mar; 26(3):257-65. PubMed ID: 16472331
[TBL] [Abstract][Full Text] [Related]
11. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
12. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Cady RK; Vause CV; Ho TW; Bigal ME; Durham PL
Headache; 2009 Oct; 49(9):1258-66. PubMed ID: 19788468
[TBL] [Abstract][Full Text] [Related]
13. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine.
Fan PC; Kuo PH; Chang SH; Lee WT; Wu RM; Chiou LC
Cephalalgia; 2009 Aug; 29(8):883-90. PubMed ID: 19236383
[TBL] [Abstract][Full Text] [Related]
14. No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine.
Cernuda-Morollón E; Riesco N; Martínez-Camblor P; Serrano-Pertierra E; García-Cabo C; Pascual J
Headache; 2016 Oct; 56(9):1448-1454. PubMed ID: 27634731
[TBL] [Abstract][Full Text] [Related]
15. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
[TBL] [Abstract][Full Text] [Related]
16. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
[TBL] [Abstract][Full Text] [Related]
17. No increase of calcitonin gene-related peptide in jugular blood during migraine.
Tvedskov JF; Lipka K; Ashina M; Iversen HK; Schifter S; Olesen J
Ann Neurol; 2005 Oct; 58(4):561-8. PubMed ID: 16178016
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
[TBL] [Abstract][Full Text] [Related]
19. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
Palma JA; Irimia P; Fernandez-Torron R; Ortega-Cubero S; Riverol M; Luquin MR; Martinez-Vila E
Rev Neurol; 2012 Jun; 54(12):705-11. PubMed ID: 22673946
[TBL] [Abstract][Full Text] [Related]
20. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
Gonzalez-Martinez A; Rodríguez Vázquez E; de la Red Gallego H; García-Azorín D; Gallego de La Sacristana M; Guerrero Peral ÁL; Gago-Veiga AB
Headache; 2020 Jan; 60(1):153-161. PubMed ID: 31691958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
